Related Experiment Video
Updated: May 7, 2026

Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations
Published on: November 7, 2019
[Hemolytic-uremic syndrome associated with gemcitabine use: report of one case]
Jorge Vega1, Christian Parodi, Gonzalo P Méndez
1Servicio de Medicina, Hospital Dr. Gustavo Fricke, Viña del Mar, Chile.
Abstract:
Gemcitabine is a widely used drug in the treatment of advanced pancreatic cancer and other malignancies. It is generally well tolerated and exceptionally its use has been associated with hemolytic-uremic syndrome, causing acute kidney injury, hypertension, chronic renal failure requiring dialysis, and death. We report a 60-year-old man with pancreatic carcinoma and regional lymph node invasion, whom after four months of therapy with gemcitabine and after dose number 11, suddenly developed an acute nephritic syndrome with moderate renal impairment, associated with severe anemia (hemoglobin 6.0 g/dL) and thrombocytopenia (20,000 mm³). Renal biopsy showed the classic findings of thrombotic microangiopathy Gemcitabine was discontinued and renal function and hematological parameters gradually improved.
Related Concept Videos
Hemodialysis II: Procedure and Complications
Nephrotic Syndrome I : Introduction
Cytotoxic Edema: Pathophysiology
Drug toxicity: Idiosyncratic Reactions
Hypersensitivity Reactions: Cytolytic Reactions
Acute Kidney Injury IV: Diagnostic Studies and Prevention

